HDAC inhibitor
Histone deacetylase inhibitor
- Alters gene transcription by preventing histone deacetylation
- Used in cutaneous T-cell lymphoma; valproate has weak activity
- Thrombocytopenia and QT prolongation
Drugs with this mechanism (11)
- Belinostat — IV HDAC inhibitor for peripheral T-cell lymphoma; UGT1A1-cleared.
- Givinostat — HDAC inhibitor that slows functional decline in Duchenne muscular dystrophy.
- Panobinostat — Oral HDAC inhibitor for myeloma; long half-life and marked QT risk.
- Romidepsin — Cyclic-peptide HDAC inhibitor for cutaneous T-cell lymphoma.
- Sodium butyrate — Short-chain fatty acid and HDAC inhibitor, taken as a supplement.
- Valproic acid — Broad-spectrum anticonvulsant and mood stabilizer; highly teratogenic and metabolically burdensome.
- Divalproex DR — Delayed-release broad-spectrum antiseizure drug and mood stabilizer; highly teratogenic.
- Divalproex ER — Extended-release broad-spectrum antiseizure drug and mood stabilizer; highly teratogenic.
- Valproate sodium IV — Intravenous valproate for seizures when oral therapy is unavailable; broad-spectrum but highly teratogenic.
- Divalproex sprinkle — Valproate sprinkle capsule for seizures; useful when intact tablets cannot be swallowed.
- Vorinostat — First-approved HDAC inhibitor, for cutaneous T-cell lymphoma.
All mechanisms · Open the interactive console ↗